Navidea biopharmaceuticals announces positive preliminary results of its ongoing phase 2b study comparing tc99m tilmanocept imaging with histopathology of joints from patients with rheumatoid arthritis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced preliminary results from the ongoing nav3-32 phase 2b study titled, “a comparison of tc99m tilmanocept quantitative imaging with immunohistochemical (ihc) analysis of cd206 expression in synovial tissue from subjects clinically diagnosed with rheumatoid arthritis (ra).
NAVB Ratings Summary
NAVB Quant Ranking